Hikma Drug Patent Portfolio
Hikma owns 8 orange book drugs protected by 26 US patents with Levothyroxine Sodium having the least patent protection, holding only 1 patent. And Vancomycin Hydrochloride with maximum patent protection, holding 6 patents. Given below is the list of Hikma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759497 | Daptomycin formulations | 28 Aug, 2038 | Active |
| US12053502 | Daptomycin formulations | 28 Aug, 2038 | Active |
| US11213480 | Phenylephrine hydrochloride ready-to-use solution | 26 Sep, 2036 | Active |
| US11471400 | Phenylephrine hydrochloride ready-to-use solution | 05 Aug, 2036 | Active |
| US11154498 | Stabilized liquid formulation of levothyroxine | 20 Jul, 2036 | Active |
| US11213498 | Aqueous formulation comprising paracetamol and ibuprofen | 14 Jan, 2036 | Active |
| US10039804 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US10188697 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US10849956 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11000567 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11517609 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11628200 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US12161690 | Glycopeptide compositions | 06 Nov, 2035 | Active |
| US11389416 | Aqueous formulation comprising paracetamol and ibuprofen | 17 Jul, 2035 | Active |
| US12083087 | Aqueous formulation comprising paracetamol and ibuprofen | 17 Jul, 2035 | Active |
| US10722510 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US10973814 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US11135155 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US11617713 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US11628139 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US11975096 | Liquid naloxone spray | 26 Aug, 2034 | Active |
| US11446266 | Combination composition | 26 Oct, 2031 | Active |
| US11896567 | Combination composition | 26 Oct, 2031 | Active |
| US6451289 | Albuterol formulations | 21 Mar, 2021 | Expired |
| US5547994 | Method for treating asthma using optically pure R(-) albuterol | 20 Aug, 2013 | Expired |
| US5362755 | Method for treating asthma using optically pure (R)-albuterol | 25 Mar, 2013 | Expired |
Latest Legal Activities on Hikma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Hikma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 13 Feb, 2024 | US11896567 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896567 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896567 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896567 |
|
Recordation of Patent Grant Mailed
Critical
| 13 Feb, 2024 | US11896567 |
|
Email Notification
Critical
| 13 Feb, 2024 | US11896567 |
|
Email Notification
Critical
| 25 Jan, 2024 | US11896567 |
|
Issue Notification Mailed
Critical
| 24 Jan, 2024 | US11896567 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jan, 2024 | US10722510 |
| Dispatch to FDC | 16 Jan, 2024 | US11896567 |
|
Application Is Considered Ready for Issue
Critical
| 16 Jan, 2024 | US11896567 |
|
Issue Fee Payment Received
Critical
| 05 Jan, 2024 | US11896567 |
|
Issue Fee Payment Verified
Critical
| 05 Jan, 2024 | US11896567 |
Hikma Drug Patents' Oppositions Filed in EPO
Hikma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15791287A | Oct, 2020 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Revoked |
Hikma's Family Patents
Hikma Drug List
Given below is the complete list of Hikma's drugs and the patents protecting them.
1. Combogesic Iv
Combogesic Iv is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11213498 | Aqueous formulation comprising paracetamol and ibuprofen |
14 Jan, 2036
(10 years from now)
| Active |
| US11389416 | Aqueous formulation comprising paracetamol and ibuprofen |
17 Jul, 2035
(10 years from now)
| Active |
| US12083087 | Aqueous formulation comprising paracetamol and ibuprofen |
17 Jul, 2035
(10 years from now)
| Active |
| US11446266 | Combination composition |
26 Oct, 2031
(6 years from now)
| Active |
| US11896567 | Combination composition |
26 Oct, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combogesic Iv's drug page
2. Daptomycin
Daptomycin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759497 | Daptomycin formulations |
28 Aug, 2038
(13 years from now)
| Active |
| US12053502 | Daptomycin formulations |
28 Aug, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daptomycin's drug page
3. Immphentiv
Immphentiv is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11213480 | Phenylephrine hydrochloride ready-to-use solution |
26 Sep, 2036
(11 years from now)
| Active |
| US11471400 | Phenylephrine hydrochloride ready-to-use solution |
05 Aug, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Immphentiv's drug page
4. Kloxxado
Kloxxado is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10722510 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
| US10973814 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
| US11135155 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
| US11617713 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
| US11628139 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
| US11975096 | Liquid naloxone spray |
26 Aug, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kloxxado's drug page
5. Levothyroxine Sodium
Levothyroxine Sodium is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11154498 | Stabilized liquid formulation of levothyroxine |
20 Jul, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levothyroxine Sodium's drug page
Explore Our Curated Drug Screens
6. Vancomycin
Vancomycin is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039804 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10188697 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10849956 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11000567 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11517609 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin's drug page
7. Vancomycin Hydrochloride
Vancomycin Hydrochloride is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039804 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10188697 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US10849956 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11517609 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US11628200 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
| US12161690 | Glycopeptide compositions |
06 Nov, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin Hydrochloride's drug page
8. Xopenex
Xopenex is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6451289 | Albuterol formulations |
21 Mar, 2021
(3 years ago)
| Expired |
| US5547994 | Method for treating asthma using optically pure R(-) albuterol |
20 Aug, 2013
(11 years ago)
| Expired |
| US5362755 | Method for treating asthma using optically pure (R)-albuterol |
25 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xopenex's drug page